Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

About this update from Corbus Pharmaceuticals Holdings, Inc.

NORWOOD, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced it will be participating in the following investor conferences. Guggenheim’s Second Annual Healthcare Innovation Conference in Boston Format: Presentation and one-on-one investor meetings Date: November 12, 2025 Presentation time: 1:00pm ET Webcast link: Click here Jefferies Global Healthcare Conference in London Format: Presentation and one-on-one investor meetings Date: November 18, 2025 Presentation time: 4:00pm GMT Webcast Link: Click here Evercore’s 8th Annual Healthcare Conference in Miami Format: Presentation and one-on-one investor meetings Date: December 2, 2025 Presentation time: 3:50pm ET Webcast Link: Click here About Corbus Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload; CRB-601, an anti-integrin monoclonal antibody that blocks TGFβ activation expressed on cancer cells; and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. Forward-Looking Statements Statements in this press release that are not statements of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, statements about Corbus’ expectations regarding the completion, timing and size of its public offering and the anticipated use of proceeds therefrom. Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “may,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering, as well as risks and uncertainties associated with Corbus’ business and finances in general, including the risks and uncertainties in the section captioned “Risk Factors” in the preliminary prospectus supplement related to the public offering that will be filed with the SEC and the Company’s most recently filed Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q. There can be no assurances that we will be able to complete the proposed offering on the anticipated terms, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Corbus undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release. INVESTOR CONTACT: Sean Moran Chief Financial Officer Corbus Pharmaceuticals [email protected] Dan Ferry Managing Director LifeSci Advisors, LLC [email protected]

View stock analysis, news, and events for Corbus Pharmaceuticals Holdings, Inc.